Table 1.
Clinicopathologic data
| Parameter | Group | Tissue (n = 84) | Serum (n = 75) |
|---|---|---|---|
| T status | 1 | 27 (32%) | 31 (41%) |
| 2 | 27 (32%) | 22 (29%) | |
| 3 | 6 (7%) | 4 (5%) | |
| 4 | 24 (29%) | 18 (25%) | |
| N status | 0 | 35 (42%) | 28 (37%) |
| 1 | 21 (25%) | 15 (20%) | |
| 2 | 14 (17%) | 10 (13%) | |
| 3 | 13 (15%) | 9 (12%) | |
| 4 | 1 (1%) | 13 (18%) | |
| M status | 0 | 70 (83%) | 4 (5%) |
| 1 | 14 (17%) | 71 (95%) | |
| ER status | Negative | 25 (30%) | 23 (31%) |
| Positive | 59 (70%) | 52 (69%) | |
| PR status | Negative | 45 (54%) | 36 (48%) |
| Positive | 39 (46%) | 39 (52%) | |
| ErbB2 status | Negative | 62 (74%) | 49 (65%) |
| Positive | 22 (26%) | 26 (35%) | |
| Grade | 1 | 9 (11%) | 14 (19%) |
| 2 | 32 (38%) | 29 (39%) | |
| 3 | 43 (51%) | 32 (42%) | |
| Stage | I | 24 (29%) | 19 (25%) |
| II | 20 (24%) | 14 (19%) | |
| III | 27 (32%) | 22 (29%) | |
| IV | 13 (15%) | 20 (27%) | |
| Disease status | Progressive | 29 (35%) | 47 (63%) |
| Nonprogressive | 55 (65%) | 28 (37%) |
ErbB2 status is determined by using the Hercep test with confirmation by FISH. Disease status is determined by using the RECIST criteria.